[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF: Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg; 2006 Feb;243(2):189-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma.
  • OBJECTIVE: For patients with laparoscopic stage M1 gastric adenocarcinoma, no resection of the primary tumor, and systemic chemotherapy, this study investigated the incidence of subsequent palliative intervention and survival.
  • SUMMARY BACKGROUND DATA: Laparoscopy was performed for patients with computed tomography scan stage M0 disease and no significant obstruction or bleeding.
  • Intervention was performed on the stomach for obstruction (33%), bleeding (8%), or perforation (1%) or on a distant site for a metastasis-related complication (20%).
  • Laparotomy was necessary in 12%; the remainder had endoscopic or radiologic procedures or radiation therapy only.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Postoperative Complications. Prognosis. Proportional Hazards Models. Prospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):1183-8 [9756030.001]
  • [Cites] J Clin Gastroenterol. 1998 Jul;27(1):63-6 [9706773.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1083-7 [10460650.001]
  • [Cites] Br J Surg. 2000 Oct;87(10):1281-3 [11044150.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):780-4 [11087645.001]
  • [Cites] Hepatogastroenterology. 2001 Jan-Feb;48(37):285-9 [11268986.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):393-9 [8790853.001]
  • [Cites] Gastrointest Endosc. 1996 Nov;44(5):536-40 [8934158.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Jan;10(1):185-201 [11406458.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1219-21 [11677934.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):72-8 [11808972.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):460-6 [11952588.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):471-5 [11952590.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):696-703 [12167585.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):459-83, xiii [12424863.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):654-63 [12839850.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):1013-21 [15194084.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1195-200 [6186352.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Surg Gynecol Obstet. 1987 Feb;164(2):151-4 [2433778.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):381-6 [2918333.001]
  • [Cites] Surgery. 1991 Nov;110(5):820-3 [1948650.001]
  • [Cites] Gastrointest Endosc. 1992 May-Jun;38(3):314-8 [1607082.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Surgery. 1996 Jun;119(6):611-4 [8650600.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):434-40 [9469326.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • (PMID = 16432351.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1448917
  •  go-up   go-down


2. Chen JL, Hong J, Lu JL, Chen MX, Chen WX, Zhu JS, Chen NW, Chen GQ, Geng JG: Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma. World J Gastroenterol; 2007 Jan 21;13(3):457-61
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma.
  • AIM: To investigate the effect of N-desulfated heparin on tumor metastasis and angiogenesis, and expression of vascular endothelial growth factor (VEGF) of orthotopic implantation of human gastric carcinoma in male severe combined immune deficiency (SCID) mice.
  • METHODS: Human gastric cancer SGC-7901 cells were orthotopically implanted into the stomach of SCID mice.
  • Tumor metastasis was evaluated histologically for metastasis under microscope.
  • VEGF mRNA expression in gastric tissue of SCID mice was detected by real time PCR.
  • RESULTS: The tumor metastasis rate was 80% in normal saline group and 20% in N-desulfated heparin group (P < 0.05).
  • No bleeding occurred in N-desulfated heparin group.
  • CONCLUSION: N-desulfated heparin can inhibit metastasis of gastric cancer by suppressing tumor VEGF expression and tumor angiogenesis, but has no obvious anticoagulant activity.
  • [MeSH-major] Carcinoma / drug therapy. Heparin / therapeutic use. Neovascularization, Pathologic / drug therapy. Stomach Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / drug effects
  • [MeSH-minor] Animals. Gene Expression / drug effects. Humans. Male. Mice. Mice, SCID. Neoplasm Metastasis / drug therapy

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1607-10 [12854175.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117 [12678905.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):206-15 [14710231.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):435-9 [14719080.001]
  • [Cites] Semin Thromb Hemost. 2004 Feb;30 Suppl 1:25-30 [15085463.001]
  • [Cites] Biomed Pharmacother. 2004 May;58(4):213-9 [15183845.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1853-9 [15274366.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):683-8 [15375485.001]
  • [Cites] Magy Onkol. 2004;48(3):235-41 [15520874.001]
  • [Cites] Glycobiology. 2005 Feb;15(2):1C-6C [15496501.001]
  • [Cites] Vasc Med. 2004 May;9(3):205-13 [15675186.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12103-13 [15647251.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):99-104 [15944775.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jul;2(7):356-63 [16075795.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2869-72 [16080539.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1133-40 [12008203.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):125-9 [12071518.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1803-12 [12087470.001]
  • [Cites] Cancer Lett. 2002 Dec 1;186(1):1-9 [12183069.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):897-900 [12378638.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):199-207 [12539174.001]
  • [Cites] J Thromb Haemost. 2003 Sep;1(9):1972-6 [12941039.001]
  • (PMID = 17230619.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 9005-49-6 / Heparin
  • [Other-IDs] NLM/ PMC4065905
  •  go-up   go-down


3. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol; 2006 Jul 28;12(28):4473-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic role of serum interleukin-18 in gastric cancer patients.
  • AIM: To determine the current status in various aspects of gastric cancer patients and to find out the clinical correlation with prognostic role of serum interleukins in Thai patients.
  • Gastric cancer was histologically proven in 51 patients and gastric ulcer in 17 patients.
  • The common presentations were weight loss (41.2%), dyspepsia (39.2%), and upper gastrointestinal bleeding (15.7%).
  • A total of 35.3% gastric cancer patients and 6.3% of gastric ulcer patients were smokers (P = 0.029).
  • Moreover, 32.4% of gastric cancer patients and 6.3% of gastric ulcer patients were alcoholic drinkers (P = 0.044).
  • Lesion location was pyloric-antrum in 39.4%, gastric body in 39.4%, upper stomach in 12.2% and entire stomach in 6.1% of the patients.
  • Surgical treatment was performed in 44.1% patients (total gastrectomy in 5.9%, subtotal gastrectomy in 32.4% and palliative bypass surgery in 5.9%).
  • Systemic chemotherapy was given as an adjuvant therapy in 8.8% patients.
  • The mean survival time was 13.03 +/- 9.75 mo.
  • The IL-18 level in gastric cancer patient group (58.54 +/- 43.96 pg/mL) was significantly higher than that in gastric ulcer patient group (30.84 +/- 11.18 pg/mL) (P = 0.0001) (95% CI was 42.20, 13.19).
  • The cut point of IL-18 for diagnosis of gastric cancer was 40 pg/mL, the positive predictive value was 92.31%.
  • The IL-6 level in gastric cancer patients with distant metastasis (20.21 +/- 9.37 pg/mL) was significantly higher than that in those with no metastasis (10.13 +/- 7.83 pg/mL) (P = 0.037) (95% CI was 19.51, 0.65).
  • The role of IL-10 and IL-12 levels in gastric cancer patients was to provide data with no significant difference.
  • CONCLUSION: These findings demonstrate that serum IL-6 and IL-18, but not IL-10 and IL-12 levels may be the useful biological markers of clinical correlation and prognostic factor in patients with gastric cancer.
  • Moreover, IL-18 could serve as a diagnostic marker for gastric cancer with a high positive predictive value.
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin-18 / blood. Stomach Neoplasms / blood. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2005;8(2):124-31 [15864720.001]
  • [Cites] Gastric Cancer. 2005;8(2):86-94 [15864715.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2661-9 [10914707.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4838-44 [10987295.001]
  • [Cites] Annu Rev Immunol. 2001;19:423-74 [11244043.001]
  • [Cites] J Med Assoc Thai. 2001 Apr;84(4):475-82 [11460956.001]
  • [Cites] J Clin Gastroenterol. 2002 Apr;34(4):416-20 [11907352.001]
  • [Cites] J Surg Res. 2004 Feb;116(2):277-87 [15013367.001]
  • [Cites] Ann Surg. 1987 Jan;205(1):1-8 [3800453.001]
  • [Cites] Cytokine. 1991 May;3(3):212-23 [1653054.001]
  • [Cites] Int J Cancer. 1991 Oct 21;49(4):513-9 [1917151.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1731-5 [8448737.001]
  • [Cites] Adv Immunol. 1993;54:1-78 [8379461.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):891-903 [8253525.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):445-51 [7920213.001]
  • [Cites] Dig Dis. 1994 Sep-Oct;12(5):276-89 [7882548.001]
  • [Cites] Nature. 1995 Nov 2;378(6552):88-91 [7477296.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):281-91 [8658212.001]
  • [Cites] Eur J Cancer Prev. 1996 Oct;5(5):405-8 [8972278.001]
  • [Cites] J R Soc Med. 1996 Dec;89(12):674-8 [9014876.001]
  • [Cites] Gut. 1997 Jun;40(6):739-44 [9245927.001]
  • [Cites] Jpn J Cancer Res. 1997 Oct;88(10):953-8 [9414656.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1441-52 [9502787.001]
  • [Cites] Annu Rev Immunol. 1998;16:495-521 [9597139.001]
  • [Cites] Br Med Bull. 1998;54(1):139-50 [9604438.001]
  • [Cites] J Leukoc Biol. 1998 Jun;63(6):658-64 [9620656.001]
  • [Cites] J Biol Regul Homeost Agents. 1998 Jan-Jun;12(1-2):38-41 [9677534.001]
  • [Cites] J Clin Immunol. 1999 Jan;19(1):1-11 [10080100.001]
  • [Cites] Eur Cytokine Netw. 2000 Mar;11(1):15-26 [10705295.001]
  • (PMID = 16874857.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-18; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4125632
  •  go-up   go-down


Advertisement
4. Benfatto G, Militello C, Zanghì G, Biondi A, Licari V, Fancello R, Furci M: [Bleeding gastric lymphoma: report of two cases]. Ann Ital Chir; 2004 May-Jun;75(3):353-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bleeding gastric lymphoma: report of two cases].
  • [Transliterated title] Linfoma gastrico sanguinante: descrizione di due casi clinici.
  • We report two cases of bleeding gastric lymphoma.
  • The stomach is the most common site of primary extranodal Non-Hodgkins Lymphomas.
  • The best treatment for primary gastric lymphoma has not yet been defined.
  • For many years the treatment of choice has been the gastric resection.
  • Helicobacter pylori (H. pylori) has been associated with many gastric pathologies, including gastric lymphoma.
  • Eradication of H. pylori is now considered essential for the treatment of this pathology, and usually consists of antibiotic therapy, combined with acid suppression by a proton pump inhibitor.
  • This simple treatment in patients with low grade histology and tumor confined to the stomach can often obviate the need for surgical intervention.
  • Surgery is a necessary treatment, independently of the grading and the staging of lymphoma, in the bleeding complication as the cases we showed.
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Biopsy. Female. Follow-Up Studies. Gastrectomy. Helicobacter Infections / complications. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Lymphatic Metastasis. Melena / etiology. Proton Pump Inhibitors. Stomach / pathology. Time Factors

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605526.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Proton Pump Inhibitors
  •  go-up   go-down


5. Feng L, Zhang G, Hu Z, Zou Y, Chen F, Zhang G, Tang L: Diagnosis and treatment of 81 patients with primary gastrointestinal lymphoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;34(7):582-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of 81 patients with primary gastrointestinal lymphoma.
  • OBJECTIVE: To analyze the status quo of the diagnosis and treatments of primary gastrointestinal lymphoma (PGIL) in order to improve it.
  • METHODS: Eighty-one patients with PGIL were analyzed retrospectively including clinical manifestations, endoscopic features, pathological features, HP infection, treatment, and prognosis.
  • RESULTS: The age of patients with gastric lymphoma was (52.84+/-15.33) years.
  • Common symptoms included abdominal pain (76.5%), gastrointestinal bleeding (55.6%), anemia (54.3%), abdominal mass (25.9%), hypoproteinemia (40.7%), bowel obstruction (11.1%), abdominal distension, vomiting, and other non-specific gastrointestinal symptoms (32.1%), weight loss (33.3%); fever (8.6%), diarrhea (7.4%), digestive tract perforation (1.2%), constipation (1.2%), and dysphagia (1.2%).
  • Endoscopic appearances were as follows: tumor type (67.7%), ulcer type (27.7%), and diffuse type (4.6%).
  • HP detection rate was 39.5% and positive rate was 37.5%.
  • A total of 69 patients received surgeries: 3 had preoperative chemotherapy, and 34 had postoperative chemotherapy.
  • Twelve patients had non-surgical treatment, 6 patients of whom had simple chemotherapy and HP eradication therapy, and the other 6 gave up during the treatment.
  • There was no significant difference in the survival rate of Stage I-II patients in the surgery alone group, surgery plus chemotherapy group, and chemotherapy and HP eradication therapy group(P>0.05).
  • Chemotherapy and HP eradication are recommended.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Endoscopy, Gastrointestinal. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648667.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Saif MW: Pancreatoblastoma. JOP; 2007;8(1):55-63
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatoblastoma (PB), or infantile pancreatic carcinoma, is an extremely rare pancreatic tumor in childhood, comprising 0.5% of pancreatic non-endocrine tumors.
  • Children with PB usually present late with upper abdominal pain and many have a palpable mass in the epigastrium.
  • Mechanical obstruction of the upper duodenum and gastric outlet by tumor in the head of the pancreas may be associated with vomiting, jaundice and gastrointestinal bleeding.
  • The treatment of choice is complete resection, that may often be curative.
  • The role of adjuvant chemotherapy or radiotherapy is still under discussion due to small number of patients treated as yet.
  • Chemotherapy regimens consisting of cyclophosphamide, etoposide, doxorubicin, and cisplatin have been used in neoadjuvant setting with anecdotal benefit.
  • Prognosis of this rare tumor is good, when resected completely.
  • On the whole, PB is regarded to be a curable tumor; hence the clinical diagnosis should be made early.
  • Awareness of this rare tumor of pancreas is essential for early detection and proper management.
  • The author review the clinical presentation, etiology, diagnosis, treatment and prognosis of PB in this presentation.

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228135.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Liu LX, Zhang WH, Jiang HC, Zhu AL, Wu LF, Qi SY, Piao DX: Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. World J Gastroenterol; 2002 Aug;8(4):663-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer.
  • AIM: Regional chemotherapy using hepatic artery catheters is a good method of treating patients with colorectal cancer liver metastases.
  • Response to the treatment was evaluated by serial determinations of plasma CEA and imaging techniques consisting of computerized tomography and sonography of liver.
  • RESULTS: Sixty-eight were performed hepatic artery chemotherapy and fifty-six were followed up among seventy-five HAC patients.
  • Twenty-two patients (39.3 %) were progressed with increased tumor size and number.
  • Complications, which occurred in 18 patients (32.1 %), were as followed: hepatic artery thrombosis in 11, Upper gastric and intestinal bleeding in 3, liver abscess in 1, pocket infection in 1, cholangitis in 1, and hepatic artery pseudo-aneurysm in one patient.
  • CONCLUSION: Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer.
  • The high response and lower complication rates prove the adjuvant treatment of colorectal cancer with this treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174375.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4656317
  •  go-up   go-down


8. Kelessis NG, Vassilopoulos PP, Lambrinakis PM, Zissis CG, Efremidou AI: Treatment-related acute gastric bleeding managed successfully with surgical devascularization. J Surg Oncol; 2000 Jun;74(2):138-40
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related acute gastric bleeding managed successfully with surgical devascularization.
  • BACKGROUND AND OBJECTIVES: Patients with gastric lymphoma treated by chemotherapy or radiation therapy are at high risk of developing complications, most commonly perforation or bleeding.
  • In any case of upper gastrointestinal tract bleeding during conservative treatment for gastric lymphoma, thorough investigation is required to exclude other causes of hemorrhage which could be managed appropriately.
  • When the source of bleeding is the tumor, the only effective measure is resection of the stomach, a very dangerous operation in these poor-risk patients.
  • METHODS: We treated 3 consecutive patients with life-threatening gastric bleeding from lymphoma treated by chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Hemorrhage / surgery. Lymphoma, Non-Hodgkin / drug therapy. Stomach / blood supply. Stomach Diseases / surgery. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10914824.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Velicković D, Sabljak P, Ebrahimi K, Bjelović M, Stojakov D, Nenadić B, Spica B, Sljukic V, Pesko P: [Upper gastrointestinal bleeding as a surgical complication of primary gastric lymphoma]. Acta Chir Iugosl; 2007;54(1):131-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upper gastrointestinal bleeding as a surgical complication of primary gastric lymphoma].
  • Primary gastric lymphomas are of the extranodal non-Hodgkin type.
  • The gastrointestinal tract is the most common site of extranodal non-Hodgkin lymphomas and accounts 30-45% of all extranodal lymphomas.
  • Primary gastric lymphoma is relatively rare tumor accounting 1-7%, of all gastric malignancies.
  • Many patients came down late with advanced disease and complications such as upper gastrointestinal bleeding.
  • Twenty to thirty percent may present with occult bleeding or hematemesis et melena while gastric obstruction and perforation are less common.
  • Gastric bleeding can also occur as a complication of chemotherapy.
  • The incidence of gastric bleeding in patients receiving chemotherapy is up to 11%.
  • Given the rate of surgical complications, especially gastric bleeding, there is still an important role for surgeon in the multimodal treatment of patients with primary gastric lymphoma.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Lymphoma, Non-Hodgkin / complications. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633873.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia and Montenegro
  • [Number-of-references] 21
  •  go-up   go-down


10. Moldovanu R, Lupaşcu C, Moldovanu CM, Dimofte G, Tuţuianu B, Târcoveanu E, Crumpei F, Ferariu D, Cozma L, Vasilescu A, Filip V, Vlad N: [Gastric stromal tumor. Case report]. Rev Med Chir Soc Med Nat Iasi; 2006 Apr-Jun;110(2):372-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric stromal tumor. Case report].
  • [Transliterated title] Tumoră gastrica stromala. Prezentare de caz.
  • Preoperative endoscopic and barium meal exams showed a submucosal tumor in the gastric fornix.
  • We performed a stapled resection of the gastric fornix associated with Hiss angle reconstruction.
  • Postoperative course was non eventful and after 3 month the patient has no recurrence.
  • CONCLUSIONS: GIST are rare gastric tumors and are usually associated with bleeding and abdominal pain.
  • Surgical resection is a safe and effective treatment.
  • The chemotherapy with tyrosine kinases competitive inhibitors (e.g. imatinib mesylate) is also recommended.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / analysis. Gastrectomy / methods. Humans. Imatinib Mesylate. Ki-67 Antigen / analysis. Male. Middle Aged. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / analysis. Pyrimidines / therapeutic use. Surgical Stapling. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17802947.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


11. Kang MH, Kim SN, Kim NK, Park YI, Kim YW, Ryu KW, Lee JH, Lee JS, Park SR: Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy. Ann Surg Oncol; 2010 Dec;17(12):3163-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy.
  • BACKGROUND: We conducted the current study to investigate the clinical outcomes of metastatic gastric carcinoma (MGC) patients who experienced gastrointestinal (GI) perforation during palliative chemotherapy and to examine the prognostic factors associated with survival after perforation.
  • METHODS: We reviewed the medical records of patients at the Center for Gastric Cancer of the National Cancer Center, Korea who developed GI perforation during palliative chemotherapy between January 2001 and December 2008.
  • RESULTS: Of the 1,856 patients who received palliative chemotherapy for MGC, 32 patients (1.7%) developed GI perforation during chemotherapy.
  • Patients with perforation at the primary gastric site were more likely to have ulcerative gastric cancer lesion (90.5 vs. 40.0%, P = 0.034) or gastric tumor bleeding (28.6 vs. 0%, P = 0.298), and less likely to have Bormann type IV (14.3 vs. 60.0%, P = 0.062), than patients with perforation at nongastric sites.
  • In 14 patients (43.8%) who resumed chemotherapy after perforation, the disease control rate was 57.1%, and median overall survival (OS) after perforation was 7.5 months [95% confidence interval (CI), 6.0-9.0 months].
  • In all patients, median OS following perforation was 4.0 months (95% CI, 1.5-6.6 months), and multivariate analysis revealed that differentiated tumor histology, response to chemotherapy before perforation, and absence of septic shock at time of perforation were significantly associated with favorable OS after perforation.
  • CONCLUSIONS: As patients experiencing GI perforation during palliative chemotherapy have heterogeneous clinical presentation, we need to adopt different approaches in the management of the patients that are compatible with the favorable prognostic factors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Signet Ring Cell / drug therapy. Intestinal Perforation / chemically induced. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Palliative Care. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585878.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Fang J, Cai SN, Jiang HF, Zhou HD, Lian YH: [Effect of chemotherapy preoperatively upon early postoperative cognitive dysfunction in eldly tumor patients]. Zhonghua Yi Xue Za Zhi; 2009 Sep 8;89(33):2319-23
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of chemotherapy preoperatively upon early postoperative cognitive dysfunction in eldly tumor patients].
  • OBJECTIVE: To investigate whether preoperative chemotherapy history could influence the incidence of early postoperative cognitive dysfunction (POCD) in elderly tumor patients.
  • METHODS: A total of 107 tumor patients (> or = 60 years old, tumor TNM stages T2 - T3, N0 - N3, ASA I -III class) undergoing elective radical surgery of gastric or colorectal cancer were selected and assigned into two groups according to preoperative chemotherapy history: with preoperative chemotherapy history group (C group, n = 52) and without preoperative chemotherapy history group (N group, n = 55).
  • RESULTS: There was no significant difference in general state of patient preoperatively health including sex ratio, body mass index, complications, cancer types and stages, ASA classification between two groups (P > 0.05).
  • Neither significant difference was found in duration of anesthesia and surgery, intra-operative bleeding volume and transfusion volume between two groups (P > 0.05).
  • Impaired incidence rate of digit-symbol substitution test, controlled oral word association test, grooved pegboard non-dominant hand test and semantic fluency test at 3 days postoperation in group C were significantly higher than those in N group (P < 0.05).
  • CONCLUSION: Chemotherapy preoperatively could increase the incidence of early postoperative cognitive dysfunction in elderly with tumor.
  • [MeSH-major] Cognition Disorders / etiology. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / psychology. Premedication. Stomach Neoplasms / drug therapy. Stomach Neoplasms / psychology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Incidence. Male. Middle Aged. Neuropsychological Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095352.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Strobl S, Zuber-Jerger I: [Acute upper gastrointestinal bleeding after coronary intervention in acute myocardial infarction]. Med Klin (Munich); 2010 Apr;105(4):296-9
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute upper gastrointestinal bleeding after coronary intervention in acute myocardial infarction].
  • HISTORY AND ADMISSION FINDINGS: A 73-year-old man with NSTEMI (non-ST segment elevation myocardial infarction) underwent coronary angiography and an in-stent restenosis and thrombosis in ramus circumflexus was found.
  • A drug-eluting stent (DES) was implanted.
  • 12 h after intervention during threefold platelet inhibition the patient presented a gastrointestinal bleeding with melena and the hemoglobin level dropped from 15.3 g/dl to 9.7 g/dl.
  • Therefore, a percutaneous coronary intervention with implantation of a DES (Taxus) was performed.
  • In gastroscopy, a 2.5-cm necrotic formation resembling a tumor with an oozing bleeding was identified.
  • The bleeding was stopped after injection of adrenaline.
  • TREATMENT AND COURSE: With high-dose proton pump blocker therapy, calculated Helicobacter pylori eradication with amoxicillin and clarithromycin, and cessation of NSAID (nonsteroidal anti-inflammatory drugs), the hemoglobin level was stable with 9.7 g/dl.
  • CONCLUSION: Bleeding complications after stent implantation create a dilemma situation.
  • The risk of a hemorrhagic shock by continuing platelet inhibition therapy and the risk of an acute stent thrombosis with interruption of the platelet inhibition should be carefully calculated considering individual facts and the guidelines.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Restenosis / therapy. Drug-Eluting Stents. Gastrointestinal Hemorrhage / chemically induced. Helicobacter Infections / diagnosis. Helicobacter pylori. Myocardial Infarction / therapy. Platelet Aggregation Inhibitors / adverse effects. Stomach Diseases / chemically induced. Stomach Ulcer / diagnosis
  • [MeSH-minor] Aged. Amoxicillin / therapeutic use. Anti-Bacterial Agents / therapeutic use. Clarithromycin / therapeutic use. Combined Modality Therapy. Drug Therapy, Combination. Gastric Mucosa / pathology. Gastroscopy. Humans. Male. Necrosis. Proton Pump Inhibitors / therapeutic use


14. Schmidt WP, Schmitz N, Sonnen R: Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma; 2004 Sep;45(9):1847-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management of gastric lymphoma: the treatment option of choice.
  • The study was initiated to assess the safety and effectiveness of primary chemotherapy (CHT) followed by radiotherapy (RT) compared to surgery prior to CHT and/or RT in the management of localized gastric lymphoma.
  • Forty patients had tumor stage IE, 36 II1E and 16 II2E (Musshoff classification).
  • No patient experienced gastric perforation or bleeding during CHT.
  • Primary CHT of localized gastric lymphoma is associated with a low risk of treatment-related complications.
  • To avoid long-term sequelae after gastric resection, primary CHT is recommended as standard initial treatment in localized gastric lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Taylor and Francis Ltd
  • (PMID = 15223645.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Sathornsumetee S, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Friedman HS, Reardon DA: Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):2045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2045 Background: Bevacizumab (B), a neutralizing VEGF monoclonal antibody, has anti-glioma activity as single agent and in combination with cytotoxic therapy.
  • Erlotinib (E), an EGFR tyrosine kinase inhibitor, may exhibit anti-tumor activity in some malignant glioma (MG) patients.
  • Key eligibility criteria included: age ≥ 18 years; KPS ≥ 60; > 4 weeks from prior surgery, XRT or chemotherapy.
  • Patients with either > 3 prior progressions, requirement for therapeutic anti-coagulation or acute hemorrhage on pre-treatment imaging were excluded.
  • There was no survival difference between EIAC and non-EIAC groups.
  • Serious side effects were rare and included two patients with pulmonary embolism, single patients with either intestinal perforation, ischemic stroke, gastric bleeding, or nasal septal perforation.
  • Pharmacokinetic and tissue biomarker profiles are in preparation.
  • CONCLUSIONS: Among heavily pretreated recurrent MG patients, bevacizumab plus erlotinib is tolerated and associated with encouraging anti-tumor benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964647.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Takagi T, Nakase Y, Fukumoto K, Miyagaki T, Ishida E, Kobayashi Y, Soga K, Kanemitsu D, Kassai K, Sakamoto K, Takenaka S, Yanagida K, Itani K, Fukumoto I: [Long-term disease-free survival following multimodal treatment in a patient with curatively unresectable advanced gastric cancer with metachronous liver metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2421-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term disease-free survival following multimodal treatment in a patient with curatively unresectable advanced gastric cancer with metachronous liver metastasis].
  • Despite a diagnosis of cStage IV gastric cancer (cN2, cH0, cM0, cT3 (SE), cP1), we preferentially performed a non-curative surgery to avoid stenosis or bleeding by tumor invasion.
  • Since no evidence of peritoneal metastasis was found at surgery, distal gastrectomy with D2 lymph node dissection was performed, and lymph nodes anterior to the pancreatic head were sampled.
  • The pathological diagnosis was pT3 (SE), pN2, sH0, pM1 (LYM), pStage IV.
  • We speculate that in the presence of N or M (LYM) factors for stage IV gastric cancer, surgery with lymphadenectomy, which does not prevent the completion of adjuvant chemotherapy, followed by multimodal treatments such as continued chemotherapy and RFA, led to the long-term survival.
  • [MeSH-major] Liver Neoplasms / secondary. Neoplasms, Second Primary / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Catheter Ablation. Combined Modality Therapy. Disease-Free Survival. Drug Combinations. Gastrectomy. Humans. Lymph Node Excision. Male. Middle Aged. Oxonic Acid / therapeutic use. Tegafur / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224593.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


17. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim HJ: A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol; 2007 Oct;37(10):744-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
  • OBJECTIVE: This phase II study was designed to assess the safety and efficacy of a modified FOLFIRI regimen (irinotecan with bi-weekly, low dose leucovorin (ldLV) and bolus and continuous infusion with 5-fluorouracil (5-FU)) as a salvage therapy for patients with advanced or metastatic gastric cancer.
  • RESULTS: A total of 36 patients were assigned to treatment.
  • Of the 30 patients evaluated for their tumor response, three achieved a partial response, with an overall response rate of 10.0% (95% CI 0.0-21.0%).
  • The median time to progression was 3.3 (95% CI 2.0-4.6) months, and the median overall survival time was 10.9 (95% CI 6.1-15.7) months.
  • The median number of cycles of modified FOLFIRI treatment was 3 (range 1-9 cycles).
  • There was one episode of UGI bleeding, but there were no treatment-related deaths.
  • CONCLUSION: The modified FOLFIRI regimen described here appears a safe and feasible salvage therapy in advanced gastric cancer patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Hematologic Diseases / chemically induced. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Nausea / chemically induced. Salvage Therapy. Stomatitis / chemically induced. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923456.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


18. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • [Transliterated title] Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • Poorly-differentiated ET's have a poor prognosis and are treated by chemotherapy.
  • Surgical excision is the only curative treatment of well-differentiated ET's.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • Ileal ET's, even if small, are malignant, frequently multiple, and complicated in 30-50% of cases by bowel obstruction, mesenteric invasion, or bleeding.
  • More than half of the cases of pancreatic ET are non-functional.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For insulinoma with NEM-I, enucleation of lesions in the pancreatic head plus a caudal pancreatectomy is the most appropriate procedure.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


19. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD: Current status of gastrointestinal carcinoids. Gastroenterology; 2005 May;128(6):1717-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local manifestations--mass, bleeding, obstruction, or perforation--reflect invasion or tumor-induced fibrosis and often result in incidental detection at emergency surgery.
  • Biochemical diagnosis is established by elevation of plasma chromogranin A (CgA), serotonin, or urinary 5-hydroxyindoleacetic acid (5-HIAA), while topographic localization is by Octreoscan, computerized axial tomography (CAT) scan, or endoscopy/ultrasound.
  • Primary therapy is surgical excision to avert local manifestations and decrease hormone secretion.
  • Chemotherapy and radiotherapy have minimal efficacy and substantially decrease quality of life.
  • Local endoscopic excision for gastric (type I and II) and rectal carcinoids may be adequate.
  • Somatostatin analogues provide the most effective symptomatic therapy, although interferon has some utility.
  • Overall 5-year survival for carcinoids of the appendix is 98%, gastric (types I/II) is 81%, rectum is 87%, small intestinal is 60%, colonic carcinoids is 62%, and gastric type III/IV is 33%.
  • [MeSH-major] Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy


20. Becker JC, Domschke W, Pohle T: Biological in vitro effects of fibrin glue: fibroblast proliferation, expression and binding of growth factors. Scand J Gastroenterol; 2004 Oct;39(10):927-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibrin glue is used in the endoscopic therapy of bleeding ulcerations.
  • Accelerated closure of ulcers has been documented for this treatment in comparison with other injection techniques; the biological reason, however, remains unclear.
  • METHODS: In an in vitro model the effects of fibrin glue on the expression and secretion of growth factors by gastric epithelial (AGS, KATO III) and mesenchymal cells (fibroblasts) as well as their proliferative response and their interaction were compared with those of other matrices.
  • The addition of fibrin glue to a collagen type I matrix led to an increased proliferation rate of gastric wall fibroblasts.
  • These findings might at least partly explain the accelerated closure of bleeding ulcers treated by fibrin glue injection.
  • [MeSH-major] Cell Proliferation / drug effects. Fibrin Tissue Adhesive / pharmacology. Fibroblasts / physiology. Platelet-Derived Growth Factor / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Base Sequence. Binding Sites. Cytokines / metabolism. Gastric Mucosa / cytology. Humans. In Vitro Techniques. Molecular Sequence Data. Probability. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Statistics, Nonparametric. Stomach Neoplasms. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15513329.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Cytokines; 0 / Fibrin Tissue Adhesive; 0 / Platelet-Derived Growth Factor; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


21. Rudzki Z, Rucińska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczyk M, Włodarska I, Stachura J: ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol; 2005;56(1):37-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare, recently defined tumor distinct in many aspects from ALK-positive anaplastic large cell lymphoma (ALCL).
  • A 48-year old man presented with a large upper neck mass growing slowly over 18 months.
  • Histologically the tumor was diagnosed as an ALK-positive diffuse large B-cell lymphoma. with plasmablastic features.
  • Large, frequently intrasinusoidal tumor cells expressed CD138, EMA, weakly IgA and kappa, but were negative for other B-cell markers, T-cell markers and CD30.
  • The patient died of massive bleeding from his decomposing tumor 3 months after the diagnosis.
  • A 49-year old man complaining of abdominal pain revealed abdominal lymphadenomegaly and a gastric infiltrate, involving the deep portions of the gastric wall.
  • The tumor showed immunoblastic/anaplastic morphology, with some Reed-Sternberg-like cells positive for ALK.
  • The tumor demonstrated similar "null" B/T phenotype with positivity for IgA, lambda, EMA and LCA.
  • The patient (stage IVB) currently undergoes chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / metabolism. Cyclophosphamide / administration & dosage. DNA, Neoplasm / analysis. Doxorubicin / administration & dosage. Fatal Outcome. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Receptor Protein-Tyrosine Kinases. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921012.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


22. Bonin AM, Yáñez JA, Fukuda C, Teng XW, Dillon CT, Hambley TW, Lay PA, Davies NM: Inhibition of experimental colorectal cancer and reduction in renal and gastrointestinal toxicities by copper-indomethacin in rats. Cancer Chemother Pharmacol; 2010 Sep;66(4):755-64
Hazardous Substances Data Bank. COPPER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate, for the first time, the efficacy of copper-indomethacin in the inhibition of aberrant crypt foci formation using the azoxymethane-induced adenocarcinoma model, to examine cell viability in the HCT-116 colorectal cancer cell line, gastrointestinal permeability, mitochondrial oxidative damage, and renal toxicity in rat models.
  • Acute gastrointestinal toxicity was measured using gastrointestinal permeability markers, gastrointestinal ulceration and bleeding, and measurement of an acute-phase protein haptoglobin.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Colorectal Neoplasms / drug therapy. Copper / adverse effects. Copper / therapeutic use. Gastrointestinal Diseases / chemically induced. Indomethacin / adverse effects. Indomethacin / therapeutic use. Kidney Diseases / chemically induced
  • [MeSH-minor] Acetylglucosaminidase / metabolism. Animals. Azoxymethane. Carcinogens. Cecum / metabolism. Cell Line, Tumor. Colon / pathology. DNA, Mitochondrial / metabolism. Drug Combinations. Duodenal Ulcer / chemically induced. Duodenal Ulcer / pathology. Electrolytes / urine. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Haptoglobins / metabolism. Hemoglobins / metabolism. Intestinal Mucosa / metabolism. Male. Permeability. Rats. Rats, Sprague-Dawley. Stomach Ulcer / chemically induced. Stomach Ulcer / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035423.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carcinogens; 0 / DNA, Mitochondrial; 0 / Drug Combinations; 0 / Electrolytes; 0 / Haptoglobins; 0 / Hemoglobins; 789U1901C5 / Copper; EC 3.2.1.52 / Acetylglucosaminidase; MO0N1J0SEN / Azoxymethane; XXE1CET956 / Indomethacin
  •  go-up   go-down


23. Fujimura M, Chin K, Sekita N, Kajimoto S, Kamijima S, Suzuki H, Ichikawa T, Mikami K: [Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy: a case report]. Hinyokika Kiyo; 2008 Dec;54(12):783-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy: a case report].
  • Cystoscopy revealed flat edematous mucosa with continuous bleeding.
  • Histopathological examination of the biopsy revealed non-Hodgkin's lymphoma of the mucosa-associated lymphoid tissue (MALT) type.
  • Results of a computed tomography scan and gallium scintigraphy suggested that it was a primary malignant lymphoma of the urinary bladder.
  • Because of the detection of a Helicobacter pylori (HP) infection in the gastric mucosal biopsy specimens, the patient was subsequently administered HP eradication therapy.
  • Consequently, the lymphoma disappeared and the woman has had no tumor recurrence for the past 25 months.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Amoxicillin / therapeutic use. Cefoperazone / therapeutic use. Cephalosporins / therapeutic use. Clarithromycin / therapeutic use. Female. Helicobacter Infections / drug therapy. Humans. Sulbactam / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. Clarithromycin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175002.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins; 5J77167P9E / cefcapene pivoxil hydrochloride; 7U75I1278D / Cefoperazone; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; S4TF6I2330 / Sulbactam
  •  go-up   go-down


24. Saif MW, Sellers S, Li M, Wang W, Cusimano L, Wang H, Zhang R: A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol; 2007 Nov;60(6):871-82
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacokinetic parameters of both drugs and their metabolites were estimated by using non-compartmental methods.
  • DLT was observed in two of six patients at irinotecan/gemcitabine 110/150 mg/m(2) (grade 3 diarrhea and grade 3 GI bleeding).
  • No patient developed acute cholinergic symptoms at any dose.
  • Tumor responses were observed in three patients (one CR: cholangiocarcinoma; two PR: SCLC, gastric neuroendocrine tumor).
  • Stable disease >3 months was found in six patients including five patients who had failed short infusions of either drug.
  • Pharmacokinetic analysis showed that C (max) of each drug and active metabolites were dose-dependent.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Area Under Curve. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Camptothecin / pharmacokinetics. Carcinoma, Small Cell / drug therapy. Cholangiocarcinoma / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacokinetics. Diarrhea / chemically induced. Dose-Response Relationship, Drug. Drug Interactions. Female. Gastrointestinal Hemorrhage / chemically induced. Half-Life. Humans. Infusions, Intravenous. Lung Neoplasms / drug therapy. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345085.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement